Community hub
Recent from talks
Contribute something to knowledge base
Content stats: 0 posts, 0 articles, 1 media, 0 notes
Members stats: 0 subscribers, 0 contributors, 0 moderators, 0 supporters
Subscribers
Supporters
Contributors
Moderators
Hub AI
Gadobutrol AI simulator
(@Gadobutrol_simulator)
Hub AI
Gadobutrol AI simulator
(@Gadobutrol_simulator)
Gadobutrol
Gadobutrol (INN; Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA). It received marketing approval in Canada and the United States. As of 2007, it was the only GBCA approved at 1.0 molar concentrations.
Gadobutrol is marketed by Bayer AG as Gadovist, by Bayer HealthCare Pharmaceuticals as Gadavist, and by GE HealthCare as PixxoScan. In India, it is also marketed by Vivere Imaging as Viv-butrol.
Gadobutrol is a medicinal product used in diagnostic magnetic resonance imaging (MRI) in adults and children. It provides contrast enhancement during cranial, spinal, breast, or other investigations. In the central nervous system, gadobutrol works by highlighting any areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity. In breast tissue, gadobutrol exposes the presence and extent of malignant breast disease. Similarly, gadobutrol is also used in contrast-enhanced magnetic resonance angiography (CE-MRA) for the diagnosis of stroke, detection of tumor perfusion, and presence of focal cerebral ischemia.
Gadobutrol should be administered intravenously by medical professionals only. Sterile techniques must always be used when preparing and administering the injection. When compared to other GBCAs, gadobutrol is available in a more concentrated form (1 mmol/mL) to alleviate a high volume of administration. The recommended dose is 0.1 mL/kg body weight.
The safety of gadobutrol was assessed throughout clinical trials and post-marketing, for multiple applications, in diverse populations and at multiple doses.
The most severe reaction to gadobutrol is nephrogenic system fibrosis (NSF) among patients with impaired elimination of the drug. The risk is highest among patients with chronic, impaired kidney function and those with acute kidney injury. NSF may result in death or severe impairment of the skin, muscle, and internal organs.
Patients who have experienced a previous adverse reaction to another contrast agent, have bronchial asthma, and/or allergic disorders have an increased risk of a hypersensitivity reaction to gadobutrol. Hypersensitivity reactions can include anaphylactoid and anaphylactic reactions ranging from mild to severe. These reactions are uncommon, however, monitoring of the patient for signs and symptoms during and after administration of gadobutrol is necessary.
Other, more mild adverse reactions have been observed in a small fraction of patients after administration. These reactions can include but are not limited to the following:
Gadobutrol
Gadobutrol (INN; Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA). It received marketing approval in Canada and the United States. As of 2007, it was the only GBCA approved at 1.0 molar concentrations.
Gadobutrol is marketed by Bayer AG as Gadovist, by Bayer HealthCare Pharmaceuticals as Gadavist, and by GE HealthCare as PixxoScan. In India, it is also marketed by Vivere Imaging as Viv-butrol.
Gadobutrol is a medicinal product used in diagnostic magnetic resonance imaging (MRI) in adults and children. It provides contrast enhancement during cranial, spinal, breast, or other investigations. In the central nervous system, gadobutrol works by highlighting any areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity. In breast tissue, gadobutrol exposes the presence and extent of malignant breast disease. Similarly, gadobutrol is also used in contrast-enhanced magnetic resonance angiography (CE-MRA) for the diagnosis of stroke, detection of tumor perfusion, and presence of focal cerebral ischemia.
Gadobutrol should be administered intravenously by medical professionals only. Sterile techniques must always be used when preparing and administering the injection. When compared to other GBCAs, gadobutrol is available in a more concentrated form (1 mmol/mL) to alleviate a high volume of administration. The recommended dose is 0.1 mL/kg body weight.
The safety of gadobutrol was assessed throughout clinical trials and post-marketing, for multiple applications, in diverse populations and at multiple doses.
The most severe reaction to gadobutrol is nephrogenic system fibrosis (NSF) among patients with impaired elimination of the drug. The risk is highest among patients with chronic, impaired kidney function and those with acute kidney injury. NSF may result in death or severe impairment of the skin, muscle, and internal organs.
Patients who have experienced a previous adverse reaction to another contrast agent, have bronchial asthma, and/or allergic disorders have an increased risk of a hypersensitivity reaction to gadobutrol. Hypersensitivity reactions can include anaphylactoid and anaphylactic reactions ranging from mild to severe. These reactions are uncommon, however, monitoring of the patient for signs and symptoms during and after administration of gadobutrol is necessary.
Other, more mild adverse reactions have been observed in a small fraction of patients after administration. These reactions can include but are not limited to the following:
Recent media
Recent media